<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="3.0" article-type="rapid-communication" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq. Bras. Cardiol.</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">DVRXTHpfkJ8QxPhGvSNkrgL</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2014000100013</article-id>
      <article-id pub-id-type="publisher-id" specific-use="previous-pid">S0066-782X2014000100013</article-id>
      <article-id pub-id-type="other">0013</article-id>
      <article-id pub-id-type="publisher-id">S0066-782X2014000100013</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20130252</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Comunica&#231;&#227;o Breve</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="pt">Obstru&#231;&#227;o Coron&#225;ria ap&#243;s Implante por Cateter de Pr&#243;tese
               Valvar A&#243;rtica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Henrique Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sarmento-Leite</surname>
            <given-names>Rog&#233;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Siqueira</surname>
            <given-names>Dimytri A. A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Luiz Ant&#244;nio</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mangione</surname>
            <given-names>Jos&#233; Armando</given-names>
          </name>
          <xref ref-type="aff" rid="aff05">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rod&#233;s-Cabau</surname>
            <given-names>Josep</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perin</surname>
            <given-names>Marco A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff06">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brito</surname>
            <given-names>F&#225;bio Sandoli de</given-names>
            <suffix>Jr.</suffix>
          </name>
          <xref ref-type="aff" rid="aff06">6</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <label>1</label>
        <institution content-type="orgname">Laval University</institution>
        <institution content-type="orgdiv1">Quebec Heart &amp; Lung Institute</institution>
        <addr-line>
          <named-content content-type="city">Quebec</named-content>
          <named-content content-type="state">Quebec</named-content>
        </addr-line>
        <country>Canad&#225;</country>
        <institution content-type="original">Quebec Heart &amp; Lung Institute, Laval
               University, Quebec City, Quebec - Canad&#225;</institution>
      </aff>
      <aff id="aff02">
        <label>2</label>
        <institution content-type="orgname">Instituto de Cardiologia do Rio Grande do
               Sul</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country>Brasil</country>
        <institution content-type="original">Instituto de Cardiologia do Rio Grande do Sul,
               Porto Alegre, RS - Brasil</institution>
      </aff>
      <aff id="aff03">
        <label>3</label>
        <institution content-type="orgname">Instituto Dante Pazzanese de
               Cardiologia</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country>
        <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o
               Paulo, SP - Brasil</institution>
      </aff>
      <aff id="aff04">
        <label>4</label>
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country>Brasil</country>
        <institution content-type="original">Hospital Pr&#243;-Card&#237;aco, Rio de Janeiro, RJ -
               Brasil</institution>
      </aff>
      <aff id="aff05">
        <label>5</label>
        <institution content-type="orgname">Hospital Benefic&#234;ncia Portuguesa de S&#227;o
               Paulo</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country>
        <institution content-type="original">Hospital Benefic&#234;ncia Portuguesa de S&#227;o Paulo, S&#227;o
               Paulo, SP - Brasil</institution>
      </aff>
      <aff id="aff06">
        <label>6</label>
        <institution content-type="orgname">Hospital Israelita Albert Einstein</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brasil</country>
        <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP -
               Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"><bold>Correspond&#234;ncia: Henrique Barbosa Ribeiro</bold>, Rua Volta Redonda, 757, apt.&#186;
               91, Campo Belo. CEP 04608-011. S&#227;o Paulo, SP - Brasil. E-mail:
                  <email>hbribeiro@cardiol.br</email>, <email>henriquebribeiro@me.com</email>
            </corresp>
        <fn fn-type="conflict">
          <p>
            <bold>Potencial Conflito de Interesses </bold>
          </p>
          <p>Os autores Fabio Sandoli de Brito Junior, Jos&#233; Armando Mangione, Josep
                  Rod&#233;s-Cabau, Luiz Antonio de Carvalho, Marco A. Perin e Rog&#233;rio Sarmento-Leite
                  receberam honor&#225;rios da ind&#250;stria (Medtronic) para consultaria e palestras. O
                  autor Josep Rod&#233;s-Cabau recebeu honor&#225;rios da ind&#250;stria (Edwards Lifesciences e
                  St. Jude Medical) para consultoria e projetos de pesquisa. O autor Dimytri A.
                  Siqueira recebeu honor&#225;rios para consultoria e palestras da ind&#250;stria (Edwards
                  Lifesciences e Medtronic).</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>102</volume>
      <issue>1</issue>
      <fpage>93</fpage>
      <lpage>96</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>08</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>02</day>
          <month>10</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
                  Commons Attribution Non-Commercial License which permits unrestricted
                  non-commercial use, distribution, and reproduction in any medium, provided the
                  original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract xml:lang="pt">
        <sec>
          <title>Fundamentos:</title>
          <p> O implante por cateter de biopr&#243;tese valvar a&#243;rtica (TAVI) consolidou-se como
                  alternativa para o tratamento de pacientes com estenose a&#243;rtica importante de alto
                  risco cir&#250;rgico. Contudo, h&#225; poucos dados na literatura com respeito &#224; obstru&#231;&#227;o
                  coron&#225;ria que, apesar de rara, trata-se de grave complica&#231;&#227;o do TAVI. </p>
        </sec>
        <sec>
          <title>Objetivo:</title>
          <p> Avaliar, no contexto brasileiro, a presen&#231;a dessa importante complica&#231;&#227;o. </p>
        </sec>
        <sec>
          <title>M&#233;todos:</title>
          <p> Foram avaliados todos os casos de obstru&#231;&#227;o coron&#225;ria inclu&#237;dos no Registro
                  Brasileiro de TAVI. Foram coletados dados cl&#237;nicos, do procedimento, do manejo e
                  de evolu&#231;&#227;o intra-hospitalar. </p>
        </sec>
        <sec>
          <title>Resultados:</title>
          <p> Entre 418 pacientes consecutivos do registro, ocorreram tr&#234;s casos de obstru&#231;&#227;o
                  coron&#225;ria (incid&#234;ncia de 0,72%). Em sua totalidade, os pacientes eram do sexo
                  feminino, sem cirurgia de revasculariza&#231;&#227;o mioc&#225;rdica (CRM) pr&#233;via, com idade
                  m&#233;dia de 85 &#177; 3 anos, EuroSCORE log&#237;stico de 15 &#177; 6% e STS de 9 &#177; 4%. Todos os
                  casos foram realizados com a v&#225;lvula bal&#227;o-expans&#237;vel Sapien XT. Em um dos
                  pacientes, com dados de tomografia computadorizada pr&#233;-procedimento,
                  verificaram-se origem das art&#233;rias coron&#225;rias baixa e seio de Valsalva estreito.
                  Todos os pacientes apresentaram-se clinicamente com hipotens&#227;o importante e
                  mantida, imediatamente ap&#243;s o implante da v&#225;lvula, e, apesar de angioplastia com
                  implante de stent, todos os pacientes foram a &#243;bito, sendo dois periprocedimento e
                  um durante hospitaliza&#231;&#227;o. </p>
        </sec>
        <sec>
          <title>Conclus&#227;o:</title>
          <p> A obstru&#231;&#227;o coron&#225;ria como complica&#231;&#227;o do TAVI, apesar de rara, &#233; potencialmente
                  fatal, podendo ocorrer mais frequentemente em mulheres e com as pr&#243;teses
                  expans&#237;veis por bal&#227;o. Fatores anat&#244;micos podem estar relacionados com sua
                  ocorr&#234;ncia, ressaltando-se a import&#226;ncia de boa avalia&#231;&#227;o pr&#233;-procedimento no
                  sentido de evitar essa grave complica&#231;&#227;o.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <kwd>Estenose da Valva A&#243;rtica</kwd>
        <kwd>Implante de Pr&#243;tese Valvar Card&#237;aca</kwd>
        <kwd>Cateteres</kwd>
        <kwd>Obstru&#231;&#227;o Coron&#225;ria</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
        <page-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>O implante por cateter da v&#225;lvula a&#243;rtica (TAVI) tem se tornado importante alternativa
            para o tratamento de pacientes com estenose a&#243;rtica de alto risco cir&#250;rgico e para
            pacientes considerados inoper&#225;veis<xref ref-type="bibr" rid="B01">1</xref>. Apesar das
            constantes melhorias nos dispositivos e da crescente experi&#234;ncia dos centros que
            realizam o procedimento, diversas complica&#231;&#245;es podem ocorrer. Dentre elas, a obstru&#231;&#227;o
            coron&#225;ria, que, apesar de rara, muita vezes &#233; fatal. A despeito de alguns relatos de
            casos e de incid&#234;ncia vari&#225;vel nos diversos registros e estudos randomizados
               (0,35-4,0%)<xref ref-type="bibr" rid="B02">2</xref>, h&#225; poucas informa&#231;&#245;es na
            literatura com respeito a seus preditores, apresenta&#231;&#227;o cl&#237;nica e tratamento. Nesse
            sentido, relatamos uma s&#233;rie de casos dessa complica&#231;&#227;o com dados obtidos do Registro
            Brasileiro de Implante de Biopr&#243;tese Valvar A&#243;rtica por Cateter.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todos</title>
      <p>Foram avaliados todos os casos de obstru&#231;&#227;o coron&#225;ria ap&#243;s implante por cateter de
            biopr&#243;tese valvar para o tratamento de estenose a&#243;rtica grave e sintom&#225;tica em pacientes
            de alto risco cir&#250;rgico, inclu&#237;dos no Registro Brasileiro de Implante por Cateter de
            Biopr&#243;tese Valvar A&#243;rtica. Dados cl&#237;nicos, do procedimento e de evolu&#231;&#227;o
            intra-hospitalar foram coletados de todos os pacientes. A obstru&#231;&#227;o coronariana foi
            definida como importante redu&#231;&#227;o do fluxo coron&#225;rio documentada por angiografia seletiva
            ou aortografia.</p>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>Entre janeiro de 2008 e janeiro de 2013, 418 pacientes foram inclu&#237;dos no Registro
            Brasileiro de TAVI, em 18 centros, dos quais 405 (96,9%) apresentavam estenose valvar
            a&#243;rtica, e 13 (3,1%), disfun&#231;&#227;o de biopr&#243;tese cir&#250;rgica. Ocorreram tr&#234;s casos (0,72%) de
            obstru&#231;&#227;o coronariana ap&#243;s TAVI, todos em valvas nativas.</p>
      <sec>
        <title>Caso 1</title>
        <p>Paciente do sexo feminino, 83 anos, hipertensa, diab&#233;tica, com doen&#231;a arterial
               coron&#225;ria e insufici&#234;ncia card&#237;aca classe funcional III (NYHA). Em avalia&#231;&#227;o cl&#237;nica,
               detectou-se estenose a&#243;rtica importante (gradiente m&#233;dio: 77 mmHg; &#225;rea valvar: 0,50
                  cm<sup>2</sup>) de alto risco cir&#250;rgico (EuroSCORE log&#237;stico: 9,5%;STS-PROM: 7,9%)
               sendo referida para TAVI. &#192; angiotomografia, verificou-se seio de Valsalva com
               di&#226;metro m&#233;dio de 26 mm, &#226;nulo valvar de 24 mm e altura das art&#233;rias coron&#225;rias
               direita (CD) e do tronco da coron&#225;ria esquerda (TCE) de 10,4 mm e 9,6 mm,
               respectivamente (<xref ref-type="fig" rid="f01">Figura 1</xref>). O procedimento foi
               realizado por via transfemoral, com implante de pr&#243;tese bal&#227;o-expans&#237;vel Sapien XT de
               26 mm. Imediatamente ap&#243;s o implante valvar, a paciente evoluiu com hipotens&#227;o
               importante e mantida, al&#233;m de supradesnivelamento do segmento ST detectado &#224;
               monitoriza&#231;&#227;o card&#237;aca. O ecocardiograma transesof&#225;gico (ETE) demonstrou adequado
               posicionamento &#192; aortografia, detectou-se obstru&#231;&#227;o completa do &#243;stio da art&#233;ria CD
                  (<xref ref-type="fig" rid="f01">Figura 1</xref>). Rapidamente instalou-se quadro
               de choque e parada cardiorrespirat&#243;ria, procedendo-se &#224;s manobras de ressuscita&#231;&#227;o
               cardiopulmonar e angioplastia com implante de dois stents farmacol&#243;gicos da art&#233;ria
               CD com sucesso (<xref ref-type="fig" rid="f01">Figura 1</xref>). Como complica&#231;&#227;o
               adicional, em fun&#231;&#227;o das manobras de reanima&#231;&#227;o, houve a perfura&#231;&#227;o do ventr&#237;culo
               direito pelo marca-passo provis&#243;rio e tamponamento, e, a despeito do tratamento das
               complica&#231;&#245;es, houve nova parada cardiorrespirat&#243;ria e &#243;bito.</p>
        <fig id="f01" fig-type="other">
          <label>Figura 1</label>
          <caption>
            <title>Tomografia computadorizada com a medida da altura das art&#233;rias coron&#225;rias
                     no eixo longo, sendo: art&#233;ria coron&#225;ria direita (a) e art&#233;ria coron&#225;ria
                     esquerda (b). Medida do seio de Valsalva obtida da m&#233;dia entre o maior e o
                     menor di&#226;metro realizado do corte transversal no eixo curto (c). Aortografia
                     demonstrando oclus&#227;o da art&#233;ria coron&#225;ria direita ap&#243;s o implante por cateter
                     da v&#225;lvula a&#243;rtica (d). Angiografia da art&#233;ria coron&#225;ria direita ap&#243;s o
                     implante de dois stents com sucesso (e).</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-102-01-0093-30252-gf01.jpg"/></fig>
      </sec>
      <sec>
        <title>Caso 2</title>
        <p>Paciente do sexo feminino, 82 anos, hipertensa e diab&#233;tica, em avalia&#231;&#227;o cl&#237;nica por
               insufici&#234;ncia card&#237;aca classe funcional II (NYHA), foi diagnosticada com estenose
               a&#243;rtica importante (gradiente m&#233;dio: 68 mmHg; &#225;rea valvar: 0,60 cm<sup>2</sup>). Em
               fun&#231;&#227;o da idade avan&#231;ada e do risco cir&#250;rgico elevado (EuroSCORE log&#237;stico: 13,3%;
               STS-PROM: 14,8%), a paciente foi referida para TAVI transfemoral, com implante de
               pr&#243;tese Sapien XT de 23 mm. Imediatamente ap&#243;s o implante valvar, a paciente evoluiu
               com hipotens&#227;o importante e mantida, sem altera&#231;&#245;es eletrocardiogr&#225;ficas. A
               aortografia de controle demonstrou obstru&#231;&#227;o completa do &#243;stio do TCE (<xref ref-type="fig" rid="f02">Figura 2</xref>). Procedeu-se ao implante de stent
               farmacol&#243;gico no TCE com restabelecimento do fluxo coron&#225;rio e revers&#227;o imediata do
               quadro de choque (<xref ref-type="fig" rid="f02">Figura 2</xref>). Ap&#243;s o
               procedimento, entretanto, detectou-se extenso acidente vascular cerebral, com o
               desenvolvimento de pneumonia e &#243;bito ap&#243;s 78 dias de interna&#231;&#227;o.</p>
        <fig id="f02" fig-type="other">
          <label>Figura 2</label>
          <caption>
            <title>Aortografia demonstrando a obstru&#231;&#227;o do tronco da coron&#225;ria esquerda ap&#243;s
                     implante percut&#226;neo valvar a&#243;rtico (a) e angioplastia com implante de stent
                     (b), demonstrando bom resultado angiogr&#225;fico final (c).</title>
          </caption>
          <graphic xlink:href="1678-4170-abc-102-01-0093-30252-gf02.jpg"/></fig>
      </sec>
      <sec>
        <title>Caso 3 </title>
        <p>Paciente do sexo feminino, 89 anos, com hist&#243;ria de hipertens&#227;o, dislipidemia e
               cardiopatia isqu&#234;mica com interven&#231;&#227;o coron&#225;ria percut&#226;nea pr&#233;via, evolu&#237;a com quadro
               de insufici&#234;ncia card&#237;aca classe funcional III (NYHA), sendo diagnosticada com
               estenose a&#243;rtica importante (gradiente m&#233;dio: 83 mmHg; &#225;rea valvar: 0,60
                  cm<sup>2</sup>). Em fun&#231;&#227;o da idade avan&#231;ada e do alto risco cir&#250;rgico (EuroSCORE
               log&#237;stico: 23,2%; STS-PROM: 5,4%), a paciente foi referida para TAVI realizado por
               via transfemoral, com implante de Sapien XT de 23 mm. Devido &#224; presen&#231;a de
               regurgita&#231;&#227;o a&#243;rtica periprot&#233;tica moderada optou-se pela realiza&#231;&#227;o de
               p&#243;s-dilata&#231;&#227;o. A aortografia e o ETE de controle revelaram redu&#231;&#227;o do grau de
               insufici&#234;ncia a&#243;rtica e aus&#234;ncia de outras complica&#231;&#245;es. Contudo, 50 minutos ap&#243;s o
               procedimento, a paciente subitamente desenvolveu hipotens&#227;o importante e mantida, e a
               aortografia evidenciou obstru&#231;&#227;o do &#243;stio do TCE. Realizada angioplastia com implante
               de stent convencional, mas a paciente persistiu em quadro de choque cardiog&#234;nico
               refrat&#225;rio, evoluindo para &#243;bito durante o procedimento de salvamento.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>Os presentes casos demonstram que a obstru&#231;&#227;o coron&#225;ria, apesar de rara, &#233; uma grave
            complica&#231;&#227;o em pacientes submetidos ao TAVI. Desde o princ&#237;pio dos procedimentos de
            TAVI, ainda em modelos experimentais, como se tratava do implante de uma pr&#243;tese
            biol&#243;gica envolta por stent e em fun&#231;&#227;o da proximidade das art&#233;rias coron&#225;rias com a
            valva a&#243;rtica, sempre houve preocupa&#231;&#227;o em rela&#231;&#227;o &#224; obstru&#231;&#227;o coron&#225;ria. De fato, a
            obstru&#231;&#227;o coron&#225;ria foi relatada nos primeiros trabalhos experimentais com pr&#243;teses
            percut&#226;neas a&#243;rticas<xref ref-type="bibr" rid="B03">3</xref>, sendo descrita
            posteriormente em seres humanos em 2006<xref ref-type="bibr" rid="B04">4</xref>. Apesar
            dessas preocupa&#231;&#245;es iniciais e de frequ&#234;ncias vari&#225;veis na literatura, atualmente, nos
            grandes registros e estudos mundiais, sua incid&#234;ncia &#233; &lt; 1%<xref ref-type="bibr" rid="B05">5</xref>. No Registro Brasileiro de TAVI, a incid&#234;ncia de obstru&#231;&#227;o
            coron&#225;ria foi bastante similar, de 0,72%. </p>
      <p>Com respeito aos mecanismos associados, pudemos observar que, ap&#243;s o implante da
            biopr&#243;tese, nos tr&#234;s casos houve o deslocamento da c&#250;spide valvar calcificada em dire&#231;&#227;o
            ao &#243;stio coron&#225;rio, mecanismo tamb&#233;m documentado na maioria dos casos da literatura<xref ref-type="bibr" rid="B02">2</xref>. Al&#233;m disso, nenhum caso ocorreu pela malha do
            stent da endopr&#243;tese nem por seu folheto<xref ref-type="bibr" rid="B02">2</xref>. Apesar
            de a pr&#243;tese autoexpans&#237;vel CoreValve apresentar dimens&#245;es aumentadas de seu stent,
            todos os casos foram documentados com a pr&#243;tese bal&#227;o-expans&#237;vel Sapien XT. A maior
            frequ&#234;ncia com esta tamb&#233;m foi sugerida na literatura, por&#233;m os mecanismos exatos para a
            sua ocorr&#234;ncia n&#227;o est&#227;o definidos<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B03">3</xref>. Fatores como o
            diferente material utilizado nas pr&#243;teses, seus mecanismos de implante, bem como os
            crit&#233;rios recomendados de implante, podem ter alguma influ&#234;ncia<xref ref-type="bibr" rid="B02">2</xref>. </p>
      <p>Apesar do mecanismo aparentemente comum entre os casos de obstru&#231;&#227;o coron&#225;ria, os
            fatores de risco para sua ocorr&#234;ncia s&#227;o bastante controversos na literatura.
            Entretanto, h&#225; evid&#234;ncia de que a baixa origem das art&#233;rias coron&#225;rias e o seio de
            Valsalva de dimens&#245;es reduzidas podem ser fatores preditores para sua ocorr&#234;ncia.<xref ref-type="bibr" rid="B02">2</xref> Em rela&#231;&#227;o a este &#250;ltimo fator de risco anat&#244;mico,
            acredita-se que o menor espa&#231;o no seio coronariano para acomodar o folheto valvar
            espesso e calcificado pode causar sua protrus&#227;o e, consequentemente, oclus&#227;o dos &#243;stios
            coronarianos. Na literatura, a m&#233;dia de altura da origem das coron&#225;rias em pacientes com
            oclus&#227;o coron&#225;ria ap&#243;s TAVI<xref ref-type="bibr" rid="B06">6</xref> &#233; menor em rela&#231;&#227;o a
            pacientes controles (m&#233;dia de 10,3 mm para o TCE <italic>versus </italic>13-15 mm do
            grupo controle; p &lt; 0,01)<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B06">6</xref>. Esse fato tamb&#233;m pode ser observado em rela&#231;&#227;o ao
            seio a&#243;rtico (m&#233;dia de 28 mm <italic>versus</italic> 32-36 mm de outros estudos na
            literatura; p &lt; 0,01)<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B06">6</xref>. </p>
      <p>Estudos pr&#233;vios de anatomia e de tomografia computadorizada demonstraram que as mulheres
            apresentam altura coron&#225;ria e seio a&#243;rtico com dimens&#245;es reduzidas em rela&#231;&#227;o aos homens
            e que, na m&#233;dia, o TCE apresenta altura reduzida em rela&#231;&#227;o &#224; art&#233;ria CD<xref ref-type="bibr" rid="B06">6</xref>. Esses estudos poderiam justificar, em parte, a
            maior frequ&#234;ncia dessa complica&#231;&#227;o nas mulheres (83% <italic>versus </italic>~50% nos
            registros; p &lt; 0,001)<xref ref-type="bibr" rid="B02">2</xref>, como em nosso estudo,
            e do acometimento preferencial do TCE. </p>
      <p>Apesar de a angioplastia coron&#225;ria poder ser realizada com alta taxa de sucesso, a
            elevada mortalidade dos pacientes ressalta a import&#226;ncia de boa avalia&#231;&#227;o e planejamento
            pr&#233;-procedimento. Identificados os fatores de risco j&#225; descritos, medidas como o
            dimensionamento menos agressivo da biopr&#243;tese e a escolha de pr&#243;teses autoexpans&#237;veis em
            detrimento das bal&#245;es-expans&#237;veis, podem prevenir a ocorr&#234;ncia dessa grave complica&#231;&#227;o.
            Adicionalmente, outras medidas preventivas, como a manuten&#231;&#227;o de fio-guia de
            angioplastia de prontid&#227;o no interior da art&#233;ria coron&#225;ria, podem tornar mais &#225;gil o
            tratamento de uma eventual obstru&#231;&#227;o coronariana. Futuros estudos incluindo maior n&#250;mero
            de casos poder&#227;o confirmar os fatores preditores, bem como o manejo mais adequado dessa
            importante complica&#231;&#227;o de TAVI.</p>
      <p>Em conclus&#227;o, a obstru&#231;&#227;o coron&#225;ria como complica&#231;&#227;o do TAVI, apesar de rara, &#233;
            potencialmente fatal, podendo ocorrer mais frequentemente em mulheres. A baixa altura
            das art&#233;rias coron&#225;rias e o seio de Valsalva reduzido podem ser fatores anat&#244;micos
            relacionados, ressaltando-se a import&#226;ncia de adequada avalia&#231;&#227;o pr&#233;-procedimento no
            sentido de tentar evitar essa complica&#231;&#227;o.</p>
    </sec>
    <sec>
      <title>Contribui&#231;&#227;o dos autores</title>
      <p>Concep&#231;&#227;o e desenho da pesquisa: Ribeiro HB, Sarmento-Leite R, Rod&#233;s-Cabau J, Brito Jr.
            FS. Obten&#231;&#227;o de dados: Ribeiro HB, Sarmento-Leite R, Siqueira DAA, Carvalho LA, Mangione
            JA, Perin MA, Brito Jr. FS. An&#225;lise e interpreta&#231;&#227;o dos dados: Ribeiro HB,
            Sarmento-Leite R, Siqueira DAA, Carvalho LA, Mangione JA, Rod&#233;s-Cabau, Perin MA, Brito
            Jr. FS. Reda&#231;&#227;o do manuscrito: Ribeiro HB, Sarmento-Leite R, Brito Jr. FS. Revis&#227;o
            cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual: Ribeiro HB, Sarmento-Leite R,
            Siqueira DAA, Carvalho LA, Mangione JA, Rod&#233;s-Cabau, Perin MA, Brito Jr. FS.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B01">
        <label>1</label>
        <mixed-citation>1. Rodes-Cabau J. Transcatheter aortic valve implantation: current and
               future approaches. Nat Rev Cardiol. 2012;9(1):15-29.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodes-Cabau</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Transcatheter aortic valve implantation: current and
                  future approaches</article-title>
          <source>Nat Rev Cardiol</source>
          <year>2012</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>15</fpage>
          <lpage>29</lpage>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <mixed-citation>2. Ribeiro HB, Nombela-Franco L, Urena M, Mok M, Pasian S, Doyle D, et
               al. Coronary obstruction following transcatheter aortic valve implantation: a
               systematic review. JACC Cardiovasc Interv. 2013;6(5):452-61.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ribeiro</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Nombela-Franco</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Urena</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mok</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pasian</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>D</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Coronary obstruction following transcatheter aortic
                  valve implantation: a systematic review</article-title>
          <source>JACC Cardiovasc Interv</source>
          <year>2013</year>
          <volume>6</volume>
          <issue>5</issue>
          <fpage>452</fpage>
          <lpage>461</lpage>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <mixed-citation>3. Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of
               artificial heart valves. Description of a new expandable aortic valve and initial
               results with implantation by catheter technique in closed chest pigs. Eur Heart J.
               1992;13(5):704-8.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Knudsen</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Hasenkam</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Transluminal implantation of artificial heart valves.
                  Description of a new expandable aortic valve and initial results with implantation
                  by catheter technique in closed chest pigs</article-title>
          <source>Eur Heart J</source>
          <year>1992</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>704</fpage>
          <lpage>708</lpage>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <mixed-citation>4. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et
               al. Percutaneous aortic valve implantation retrograde from the femoral artery.
               Circulation. 2006;113(6):842-50.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Webb</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Chandavimol</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Ricci</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Carere</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Munt</surname>
              <given-names>BI</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Percutaneous aortic valve implantation retrograde from
                  the femoral artery</article-title>
          <source>Circulation</source>
          <year>2006</year>
          <volume>113</volume>
          <issue>6</issue>
          <fpage>842</fpage>
          <lpage>850</lpage>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <mixed-citation>5. Khatri PJ, Webb JG, Rodes-Cabau J, Fremes SE, Ruel M, Lau K, et al.
               Adverse effects associated with transcatheter aortic valve implantation: a
               metaanalysis of contemporary studies. Ann Intern Med.
               2013;158(1):35-46.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khatri</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Rodes-Cabau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fremes</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Ruel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>K</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Adverse effects associated with transcatheter aortic
                  valve implantation: a metaanalysis of contemporary studies</article-title>
          <source>Ann Intern Med</source>
          <year>2013</year>
          <volume>158</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>46</lpage>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <mixed-citation>6. Buellesfeld L, Stortecky S, Kalesan B, Gloekler S, Klattab AA,
               Nietlespach F, et al. Aortic root dimensions among patients with severe aortic
               stenosis undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv.
               2013;6(1):72-83.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buellesfeld</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stortecky</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalesan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gloekler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klattab</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Nietlespach</surname>
              <given-names>F</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Aortic root dimensions among patients with severe aortic
                  stenosis undergoing transcatheter aortic valve replacement</article-title>
          <source>JACC Cardiovasc Interv</source>
          <year>2013</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>72</fpage>
          <lpage>83</lpage>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>
          <bold>Vincula&#231;&#227;o Acad&#234;mica </bold>
        </p>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>
          <bold>Fontes de Financiamento </bold>
        </p>
        <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article id="SA1" article-type="translation" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Coronary Obstruction Following Transcatheter Aortic Valve
               Implantation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Henrique Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff07">1</xref>
          <xref ref-type="corresp" rid="c02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sarmento-Leite</surname>
            <given-names>Rog&#233;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff08">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Siqueira</surname>
            <given-names>Dimytri A. A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff09">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Luiz Ant&#244;nio</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mangione</surname>
            <given-names>Jos&#233; Armando</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rod&#233;s-Cabau</surname>
            <given-names>Josep</given-names>
          </name>
          <xref ref-type="aff" rid="aff07">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perin</surname>
            <given-names>Marco A.</given-names>
          </name>
          <xref ref-type="aff" rid="aff12">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brito</surname>
            <given-names>F&#225;bio Sandoli de</given-names>
            <suffix>Jr.</suffix>
          </name>
          <xref ref-type="aff" rid="aff12">6</xref>
        </contrib>
      </contrib-group>
      <aff id="aff07">
        <label>1</label>
        <institution content-type="orgname">Laval University</institution>
        <institution content-type="orgdiv1">Quebec Heart &amp; Lung Institute</institution>
        <addr-line>
          <named-content content-type="city">Quebec</named-content>
          <named-content content-type="state">Quebec</named-content>
        </addr-line>
        <country>Canada</country>
        <institution content-type="original">Quebec Heart &amp; Lung Institute, Laval
               University, Quebec City, Quebec - Canada</institution>
      </aff>
      <aff id="aff08">
        <label>2</label>
        <institution content-type="orgname">Instituto de Cardiologia do Rio Grande do
               Sul</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country>Brazil</country>
        <institution content-type="original">Instituto de Cardiologia do Rio Grande do Sul,
               Porto Alegre, RS - Brazil</institution>
      </aff>
      <aff id="aff09">
        <label>3</label>
        <institution content-type="orgname">Instituto Dante Pazzanese de
               Cardiologia</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brazil</country>
        <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o
               Paulo, SP - Brazil</institution>
      </aff>
      <aff id="aff10">
        <label>4</label>
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country>Brazil</country>
        <institution content-type="original">Hospital Pr&#243;-Card&#237;aco, Rio de Janeiro, RJ -
               Brazil</institution>
      </aff>
      <aff id="aff11">
        <label>5</label>
        <institution content-type="orgname">Hospital Benefic&#234;ncia Portuguesa de S&#227;o
               Paulo</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brazil</country>
        <institution content-type="original">Hospital Benefic&#234;ncia Portuguesa de S&#227;o Paulo, S&#227;o
               Paulo, SP - Brazil</institution>
      </aff>
      <aff id="aff12">
        <label>6</label>
        <institution content-type="orgname">Hospital Israelita Albert Einstein</institution>
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <country>Brazil</country>
        <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP -
               Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c02"><bold>Mailing Address: Henrique Barbosa Ribeiro</bold>, Rua Volta Redonda, 757, apto.
               91, Campo Belo. Postal Code 04608-011. S&#227;o Paulo, SP - Brazil. E-mail:
                  <email>hbribeiro@cardiol.br</email>, <email>henriquebribeiro@me.com</email>
            </corresp>
        <fn fn-type="conflict">
          <p>
            <bold>Potential Conflict of Interest</bold>
          </p>
          <p>The authors Drs. Fabio Sandoli de Brito Junior, Jos&#233; Armando Mangione, Josep
                  Rod&#233;s-Cabau, Luiz Antonio de Carvalho, Marco A. Perin and Rog&#233;rio Sarmento-Leite
                  received honoraria from industry (Medtronic) on consulting and lectures. The
                  author Dr. Josep Rod&#233;s-Cabau received honoraria from industry (Edwards
                  Lifesciences and St. Jude Medical) on consulting and research projects. The author
                  Dr. Dimytri A. Siqueira received honoraria from industry (Edwards Lifesciences and
                  Medtronic) on consulting and lecture.</p>
        </fn>
      </author-notes>
      <abstract xml:lang="en">
        <sec>
          <title>Background:</title>
          <p> Transcatheter aortic valve implantation (TAVI) was established as an important
                  alternative for high-risk patients with severe aortic stenosis. However, there are
                  few data in the literature regarding coronary obstruction, that although rare, is
                  a potentially fatal complication. </p>
        </sec>
        <sec>
          <title>Objective:</title>
          <p> Evaluate this complication in Brazil.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p> We evaluated all patients presenting coronary obstruction from the Brazilian
                  Registry of TAVI. Main baseline and procedural characteristics, management of the
                  complication, and clinical outcomes were collected from all patients.</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p> From 418 consecutive TAVI procedures, coronary obstruction occurred in 3 cases
                  (incidence of 0.72%). All patients were women, without prior coronary artery
                  bypass grafting (CABG), and with mean age of 85 &#177; 3 years, logistic EuroSCORE of
                  15 &#177; 6% and STS-PROM score of 9 &#177; 4%. All of the cases were performed with
                  balloon-expandable Sapien XT prosthesis. In one patient, with pre-procedural
                  computed tomography data, coronary arteries presented a low height and a narrow
                  sinus of Valsalva. All patients presented with clinically significant severe
                  maintained hypotension, immediately after valve implantation, and even though
                  coronary angioplasty with stent implantation was successfully performed in all
                  cases, patients died during hospitalization, being two periprocedurally.</p>
        </sec>
        <sec>
          <title>Conclusion:</title>
          <p> Coronary obstruction following TAVI is a rare but potentially fatal complication,
                  being more frequent in women and with the balloon-expandable prosthesis.
                  Anatomical factors might be related with its increased occurrence, highlighting
                  the importance of a good pre-procedural evaluation of the patients in order to
                  avoid this severe complication.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <kwd>Aortic Valve Stenosis</kwd>
        <kwd>Transcatheter Aortic Valve Implantation</kwd>
        <kwd>Catheters</kwd>
        <kwd>Coronary Obstruction</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
        <page-count count="4"/>
      </counts>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Transcatheter aortic valve implantation (TAVI) has become an important alternative
               for the treatment of high-risk patients with severe aortic stenosis and those
               considered inoperable<xref ref-type="bibr" rid="B01">1</xref>. Regardless of the
               constant device improvements and growing experience of centers performing the
               procedure, several complications may occur. Among them, there is coronary
               obstruction, that although rare, is potentially fatal. Despite case reports and the
               variable incidence among large registries and randomized studies (0.35-4.0%)<xref ref-type="bibr" rid="B02">2</xref>, there is little information about predictors,
               clinical presentation and treatment. Thus, we report a series of cases of this
               complication based on data obtained from the Brazilian Registry of TAVI.</p>
      </sec>
      <sec sec-type="methods">
        <title>Methods</title>
        <p>We evaluated all cases of coronary obstruction after TAVI for the treatment of severe
               and symptomatic aortic stenosis in high-risk patients, included in the Brazilian
               Registry of TAVI. Main baseline and procedural characteristics, management of the
               complication, and clinical outcomes were collected from all patients. Coronary
               obstruction was defined as an important decrease in coronary flow documented by
               selective angiography or aortography.</p>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p>From January 2008 and January 2013, 418 patients were included in the Brazilian
               Registry of TAVI at 18 centers, of which 405 (96.9%) showed aortic valve stenosis and
               13 (3.1%) dysfunction of surgical bioprosthesis. There were 3 cases (0.72%) of
               coronary obstruction after TAVI, all in native valves. </p>
        <sec>
          <title>Case 1</title>
          <p>A 83-year-old female, hypertensive, diabetic, with coronary artery disease and
                  heart failure functional class III (NYHA). In clinical evaluation, it was noted
                  severe aortic stenosis (mean gradient: 77 mmHg; valve area: 0.50 cm<sup>2)</sup>
                  of high risk (logistic EuroSCORE: 9.5%; STS PROM: 7.9%) being referred to TAVI. On
                  angiotomography it was verified the sinus of Valsalva with mean diameter of 26 mm,
                  valve annulus of 24 mm and height of right coronary artery (RCA) and left main
                  (LM) of 10.4 mm and 9.6 mm, respectively (<xref ref-type="fig" rid="f03">Figure
                     1</xref>). The procedure was performed by transfemoral approach, with
                  implantation of a 26 mm balloon-expandable Sapien XT prosthesis. Immediately after
                  valve implantation, the patient evolved with severe and maintained hypotension, in
                  addition to ST-segment elevation detected on cardiac monitoring. Transesophageal
                  echocardiogram (TEE) showed appropriate bioprosthesis positioning, with mild
                  perivalvular regurgitation. On aortography it was detected complete obstruction of
                  RCA ostium (<xref ref-type="fig" rid="f03">Figure 1</xref>). A condition of shock
                  and cardiac arrest had quickly begun, so that cardiopulmonary resuscitation and
                  angioplasty with implantation of 2 drug-eluting stent of the RCA were successfully
                  performed (<xref ref-type="fig" rid="f03">Figure 1</xref>). As a further
                  complication, due to resuscitation procedures, there was a perforation on right
                  ventricle by temporary pacemaker and tamponade, and despite the treatment of the
                  complications, there was another cardiac arrest and subsequent death.</p>
          <fig id="f03" fig-type="other">
            <label>Figure 1</label>
            <caption>
              <title>Computed tomography with height measurement of coronary arteries in
                        long-axis view, showing right coronary artery (a) and left coronary artery
                        (b). Sinus of Valsalva measurement obtained from the mean between the larger
                        and smallest diameter on short-axis view (c). Aortography showing occlusion
                        of right coronary artery after transcatheter aortic valve implantation (d).
                        Angiography of right coronary artery after successful implantation of two
                        stents (e).</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-102-01-0093-30252-gf01-en.jpg"/></fig>
        </sec>
        <sec>
          <title>Case 2</title>
          <p>A 82-year-old female, hypertensive and diabetic, in clinical evaluation due to
                  functional class II (NYHA) heart failure, was diagnosed with significant aortic
                  stenosis (mean gradient: 68 mmHg; valve area: 0.60 cm<sup>2</sup>). Based on her
                  age and high risk (logistic EuroSCORE: 13.3%; STS-PROM: 14.8%), the patient was
                  referred to transfemoral TAVI, with implantation of a 23 mm Sapien XT prosthesis.
                  Immediately after valve implantation, the patient developed severe and maintained
                  hypotension, without electrocardiographic changes. Control aortography showed
                  complete obstruction of LM ostium (<xref ref-type="fig" rid="f04">Figure
                  2</xref>). Drug-eluting stent implantation in the LM was performed with
                  restoration of coronary flow and immediate reversal of shock condition (<xref ref-type="fig" rid="f04">Figure 2</xref>). After the procedure, however, a
                  severe stroke was detected, with development of pneumonia and death after 78 days
                  of hospitalization.</p>
          <fig id="f04" fig-type="other">
            <label>Figure 2</label>
            <caption>
              <title>Aortography showing obstruction of the left main after transcatheter
                        aortic valve implantation (a), and angioplasty with stent implantation (b)
                        showing good final angiographic result (c).</title>
            </caption>
            <graphic xlink:href="1678-4170-abc-102-01-0093-30252-gf02-en.jpg"/></fig>
        </sec>
        <sec>
          <title>Case 3</title>
          <p>A 89-year-old female, with history of hypertension, dyslipidemia and ischemic
                  cardiomyopathy with previous percutaneous coronary intervention, was developing
                  heart failure functional class III (NYHA), being diagnosed with significant aortic
                  stenosis (mean gradient: 83 mmHg; valve area: 0.60 cm<sup>2</sup>). Based on her
                  age and high risk (logistic EuroSCORE: 23.2%; STS-PROM: 5.4%), the patient was
                  referred to TAVI, that was performed by the transfemoral approach, with
                  implantation of a 23 mm Sapien XT. Due to the presence of moderate periprosthetic
                  aortic regurgitation, post-dilation was carried out. Control aortography and TEE
                  revealed a decrease in aortic regurgiration and the absence of other
                  complications. However, 50 minutes after procedure, the patient suddenly developed
                  severe and maintained hypotension, and aortography showed obstruction of the LM
                  ostium. Despite successful implantation of a bare-metal stent, the patient
                  persisted in refractory cardiogenic shock, leading to death.</p>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>These cases show that coronary obstruction, although rare, is a severe complication
               in patients undergoing TAVI. Since the beginning of TAVI procedures, still in the
               first experimental procedures, coronary obstruction has always been a concern, due to
               the implantation of biological valve surrounded by a stent frame and due to the
               proximity of the coronary arteries with the aortic valve. In fact, coronary
               obstruction was reported in the first experimental studies with percutaneous aortic
                  bioprosthesis<xref ref-type="bibr" rid="B03">3</xref>, being further described in
               humans in 2006<xref ref-type="bibr" rid="B04">4</xref>. Despite these initial
               concerns and variable frequencies in the literature, currently, in the major
               registries and studies worldwide, its incidence is &lt; 1%<xref ref-type="bibr" rid="B05">5</xref>. In the Brazilian Registry of TAVI, coronary obstruction
               incidence was very similar, of 0.72%.</p>
        <p>With respect to associated mechanisms, we can observe that, after implantation of
               bioprosthesis, in all three cases there was a displacement of calcified valve cusp
               towards coronary ostium, a mechanism also verified in most cases in the
                  literature<xref ref-type="bibr" rid="B02">2</xref>. Moreover, no case occurred
               through the endoprosthesis stent frame, nor through its leaflet<xref ref-type="bibr" rid="B02">2</xref>. Despite the fact that the self-expandable CoreValve prosthesis
               present increased dimensions of its stent, all cases were documented with
               balloon-expandable Sapien XT prosthesis. The highest frequency with the latter was
               also suggested in the literature, however, the exact mechanisms for its occurrence
               are not defined<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B03">3</xref>. Factors such as the different material used in
               prostheses, their implantation mechanisms, as well as recommended criteria for
               implantation, may have some influence<xref ref-type="bibr" rid="B02">2</xref>.</p>
        <p>Although the mechanism is apparently common among coronary obstruction cases, risk
               factors for their occurrence are very controversial in the literature. However, there
               is evidence that the low origin of coronary arteries and sinus of Valsalva with
               reduced dimensions, may be predictors of its occurrence<xref ref-type="bibr" rid="B02">2</xref>. Regarding the latter anatomical risk factor, it is believed
               that the smaller space in coronary sinus to accommodate the thick and calcified valve
               leaflet, may cause its protrusion and, consequently, occlusion of coronary ostia. In
               the literature, the mean height of the coronary origin in patients with coronary
               occlusion after TAVI<xref ref-type="bibr" rid="B06">6</xref>, is lower than control
               patients (mean of 10.3 mm for LM vs. 13-15 mm for control group; p &lt; 0.01)<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B06">6</xref>. This fact can also be observed in aortic sinus (mean of 28 mm vs. 32-36
               mm from other studies in the literature; p &lt; 0,01)<xref ref-type="bibr" rid="B02">2</xref><sup>,</sup><xref ref-type="bibr" rid="B06">6</xref>.</p>
        <p>Previous studies on anatomy and computed tomography have shown that women have
               coronary height and aortic sinus with reduced dimensions compared to men, and on
               average, LM shows reduced height in relation to RCA<xref ref-type="bibr" rid="B06">6</xref>. These studies could partly explain the higher frequency of this
               complication in women (83% versus ~50% in registries; p &lt; 0.001)<xref ref-type="bibr" rid="B02">2</xref>, as in our study, and preferential involvement
               of LM.</p>
        <p>Although coronary angioplasty can be performed with high rate of success, the
               increased mortality of patients highlights the importance of a proper evaluation and
               pre-procedural planning. After identifying the risk factors above described,
               measurements such as less aggressive dimensioning of the bioprosthesis and the
               selection of a self expandable prosthesis instead of balloon expandable, could
               prevent the occurrence of this severe complication. Additionally, other preventive
               measures such as the a coronary guidewire protection, could speed up the treatment of
               a possible coronary obstruction. Future studies including a larger number of cases
               may confirm the predictors as well as a more proper management of this significant
               TAVI complication.</p>
        <p>In conclusion, coronary obstruction following TAVI is a rare but potentially fatal
               complication, being more frequent in women. Low lying coronary ostia and small sinus
               of Valsalva may be anatomical risk factors, emphasizing the importance of a proper
               pre-procedural evaluation in order to avoid this complication.</p>
      </sec>
      <sec>
        <title>Author contributions</title>
        <p>Conception and design of the research: Ribeiro HB, Sarmento-Leite R, Rod&#233;s-Cabau J,
               Brito Jr. FS. Acquisition of data: Ribeiro HB, Sarmento-Leite R, Siqueira DAA,
               Carvalho LA, Mangione JA, Perin MA, Brito Jr. FS. Analysis and interpretation of the
               data: Ribeiro HB, Sarmento Leite R, Siqueira DAA, Carvalho LA, Mangione JA, Rod&#233;s
               Cabau, Perin MA, Brito Jr. FS. Writing of the manuscript: Ribeiro HB, Sarmento-Leite
               R, Brito Jr. FS. Critical revision of the manuscript for intellectual content:
               Ribeiro HB, Sarmento Leite R, Siqueira DAA, Carvalho LA, Mangione JA, Rod&#233;s-Cabau,
               Perin MA, Brito Jr. FS.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>
            <bold>Study Association</bold>
          </p>
          <p>This study is not associated with any post-graduation program.</p>
        </fn>
        <fn fn-type="financial-disclosure">
          <p>
            <bold>Sources of Funding</bold>
          </p>
          <p>There were no external funding sources for this study.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
